Stockscreener 앱 받기
285.04
1.07%
3.03
전일 마감가:
$282.01
열려 있는:
$284.17
하루 거래량:
264.60K
Relative Volume:
0.89
시가총액:
$8.27B
수익:
$290.51M
순이익/손실:
$89.16M
주가수익비율:
95.33
EPS:
2.99
순현금흐름:
$119.18M
1주 성능:
+9.04%
1개월 성능:
+19.49%
6개월 성능:
+89.93%
1년 성능:
+96.84%
1일 변동 폭
$282.00
$289.78
1주일 범위
$257.00
$295.98
52주 변동 폭
$122.80
$295.98
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
KRYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
285.04 | 8.18B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-05 | 개시 | Jefferies | Buy |
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Activity Recap: Will Krystal Biotech Inc outperform small cap indexes2025 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Krystal Biotech (KRYS) Price Target Increased by 18.96% to 269.93 - Nasdaq
Krystal Biotech (BIT:1KRYS) Price Target Increased by 19.80% to 226.45 - Nasdaq
Movement Recap: What is Krystal Biotech Inc.’s market position2025 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - sharewise.com
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price - MarketBeat
Avoiding Lag: Real-Time Signals in (KRYS) Movement - Stock Traders Daily
Krystal Biotech stock maintains Buy rating at H.C. Wainwright on strong revenue - Investing.com Canada
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
Credo Technology Group Holding And 2 Insider Picks For Strong Growth - Yahoo Finance
Krystal Biotech Reports ~$389M 2025 VYJUVEK Revenue, $955M Cash Reserves - Nasdaq
Krystal Biotech expects Vyjuvek net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Rpt-Krystal Biotech Expects VYJUVEK Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Krystal Biotech Announces Preliminary 4Q 2025 VYJUVEK Revenue of $106-$107 Million and Strategic Vision for Growth in Rare Disease Market - Quiver Quantitative
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Krystal Biotech expects net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Krystal Biotech Expects Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Inside one company's plan to reach 10,000 rare disease patients - Stock Titan
Krystal Biotech rises on new phase 1 data for cystic fibrosis asset - MSN
Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025 - Intellectia AI
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing - Yahoo Finance
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
KRYS: TD Cowen Raises Price Target and Maintains Buy Rating | KR - GuruFocus
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update - Yahoo Finance
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Krystal Biotech (KRYS) Rises on Positive Phase 1 Data for Cystic Fibrosis Treatment - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7%Still a Buy? - MarketBeat
Krystal Biotech stock price target raised to $306 by TD Cowen on CF data - Investing.com Canada
Krystal Biotech stock hits all-time high at 265.99 USD By Investing.com - Investing.com Canada
Citigroup Raises Price Target for Krystal Biotech (KRYS) to $320 - GuruFocus
Krystal Biotech stock hits all-time high at 265.99 USD - Investing.com India
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why - Yahoo Finance
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Krystal Biotech stock price target raised to $288 from $272 at BofA - Investing.com Canada
Aug Momentum: Will Krystal Biotech Inc. stock reach all time highs in 2025 - Улправда
KRYS: HC Wainwright & Co. Raises Price Target to $310 | KRYS Sto - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Jefferies raises Krystal Biotech stock price target to $310 on CF data By Investing.com - Investing.com South Africa
Jefferies raises Krystal Biotech stock price target to $310 on CF data - Investing.com Australia
Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data - Sahm
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path - Yahoo Finance
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):